Céline Ducournau1, Thi Tl Nguyen1, Rodolphe Carpentier2,3, Isabelle Lantier4, Stéphanie Germon1, Flavien Précausta1, Pierre-Jean Pisella1, Hervé Leroux4, Nathalie Van Langendonck5, Didier Betbeder2,3, Isabelle Dimier-Poisson1. 1. Immunologie Parasitaire et Vaccinologie, Biothérapies Anti-Infectieuses, Université de Tours-INRA, UMR1282 Infectiologie et Santé Publique, UFR Pharmacie, F-37000 Tours, France. 2. Centre International de Recherche sur l'Inflammation de Lille LIRIC -UMR 995 Inserm/Université Lille 2/CHRU Lille. Innovation thérapeutique ciblant l'inflammation. Groupe Nanomédecine, Faculté de Médecine, F-59045 Lille Cedex, France. 3. Université d'Artois, rue du Temple, 62030 ARRAS, France. 4. Laboratoire d'Expertise en Infection Animale, INRA-Université de Tours, UMR1282 Infectiologie et Santé Publique, F-37380 Nouzilly, France. 5. Service de Parasitologie-Mycologie-Médecine Tropicale, CHRU, Tours, France.
Abstract
AIM: Development of protein vaccine to prevent congenital infection is a major public health priority. Our goal is the design of mucosal synthetic pathogen inducing protective immune responses against congenital toxoplasmosis. MATERIALS & METHODS: Mice were immunized intranasally, establishing pregnancy and challenging orally. Placental immune response, congenital infection, pup growth, parasitic load rates were studied. RESULTS: Pups born to vaccinated infected dams had significantly fewer brain cysts, no intraocular inflammation and normal growth. Protection was associated with a placental cellular Th1 response downregulated by IL-6 and correlated with persistence of vaccine for few hours in the nose before being totally eliminated. CONCLUSION: Our vaccine conferred high protection against congenital toxoplasmosis. These results provide support for future studies of other congenital vaccine.
AIM: Development of protein vaccine to prevent congenital infection is a major public health priority. Our goal is the design of mucosal synthetic pathogen inducing protective immune responses against congenital toxoplasmosis. MATERIALS & METHODS:Mice were immunized intranasally, establishing pregnancy and challenging orally. Placental immune response, congenital infection, pup growth, parasitic load rates were studied. RESULTS: Pups born to vaccinated infected dams had significantly fewer brain cysts, no intraocular inflammation and normal growth. Protection was associated with a placental cellular Th1 response downregulated by IL-6 and correlated with persistence of vaccine for few hours in the nose before being totally eliminated. CONCLUSION: Our vaccine conferred high protection against congenital toxoplasmosis. These results provide support for future studies of other congenital vaccine.